Evaluating Multiple Versions of Cellular and Gene Therapies: FDA IND Guidance
“Explore FDA guidance on evaluating multiple versions of cellular and gene therapies in early-phase trials. Learn about IND submission efficiency and CBER’s umbrella trial approach.” Introduction: The Need for Streamlined Evaluation of Cellular and Gene Therapies Under many traditional clinical trial conditions, a single investigational product requires an individual Investigational New Drug (IND) application whenever […]
CBER’s Role in Advancing Cellular and Gene Therapies | BioBoston Consulting
“Learn how CBER oversees cellular and gene therapy approvals, ensuring safety, efficacy, and innovation in life sciences. Discover the future of molecular medicine.” We will explain the ways in which Center for Biologics Evaluation and Research (CBER) has regulatory authority over these novel therapies via the Public Health Service Act and the Federal Food Drug […]
CAPA’s Impact on Quality: Enhancing Medical Device Compliance and Safety
“Learn how Corrective and Preventive Action (CAPA) in medical devices drives quality, compliance, and patient safety. Explore CAPA process under Title 21 CFR Part 820.” Corrective and preventive action (CAPA) is one of the most critical elements of Title 21 CFR Part 820, because it creates a foundation for continuous improvement in the industry. In […]
Can Innovation and Regulation Coexist in Life Sciences? Balancing Progress and Safety
“Explore the balance between innovation and regulation in life sciences, from gene therapies to precision medicine, and how they can coexist to drive progress safely.” Does innovation and regulation coexist peacefully or are they simply two sides of the corporate coin destined to battle forever? Amidst the dynamic and rapid pace of life science […]
Bridging Quality Gaps: Achieving Regulatory Excellence in Biotech, Pharma & Medical Devices
“Learn how BioBoston Consulting helps organizations bridge quality gaps, achieve regulatory excellence, and maintain compliance in biotech, pharma, and medical devices.” Let us guide you through the key foundations of regulatory excellence and quality assurance built for success. Seamless regulatory compliance and superior quality is non-negotiable in the fast-paced world of biotechnology, pharmaceuticals & medical […]
Avoiding Issues in Laboratory Controls: FDA cGMP Compliance for Pharmaceutical Testing
“Learn how to meet FDA cGMP laboratory control requirements for pharmaceutical testing, including sampling, sterility testing, validation of test methods, and quality control in drug manufacturing.” As part of this wide umbrella of regulations, Subpart I specifically addresses laboratory controls due to their importance in ensuring the quality of products and conformance to specifications. Laboratory […]
FDA cGMP Compliance for Automatic, Mechanical & Electronic Equipment in Drug Manufacturing
“Learn about FDA cGMP regulations for automatic, mechanical, and electronic equipment used in drug manufacturing. Ensure compliance with calibration, inspection, and documentation requirements.” It is important to maintain the highest standards and comply with stringent regulations to guarantee drug safety and performance. Among them, Title 21, Chapter I of the Food and Drug Administration (FDA) […]
Achieving Compliance with FDA’s cGMP Regulations: Essential Guidelines for Pharmaceutical Manufacturers
“Learn how pharmaceutical manufacturers can achieve compliance with FDA cGMP regulations, ensuring safety, quality, and efficacy in drug production.” The pharmaceutical industry is formally regulated to ensure the safety, efficacy, and quality of the relevant drugs on a national and international level. For instance, one of the most basic regulations is Title 21 Food and […]
A Guide to CFR 21 PART 211 Subpart C Regulations for Drug Manufacturing Facilities
Learn about CFR 21 PART 211 Subpart C regulations for drug manufacturing facilities, covering design, maintenance, utilities, and equipment compliance. The Code of Federal Regulations (CFR) 21 PART 211 Subpart C [211.42 – 211.162] lays out the regulations for buildings and facilities used in the manufacture, processing, packing or holding of drug products. Regulations cover […]